CARIS LIFE SCIENCES, INC. vs NATERA, INC., two Medical Diagnostics stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Caris and Natera occupy the same molecular-diagnostics aisle with opposite income statements mid-flight: Caris just profitable, a 3.8% net margin priced at 52.9 times earnings; Natera still spending, a negative 9.1% net margin carried by a $37B valuation, seven times Caris' size. Natera got to scale first, prenatal screening funding its oncology push, and the market pays for that altitude even at a loss; Caris' tumor-profiling franchise is smaller, tidier, and cheaper in absolute terms. Both hold defensive liquidity, current ratios near 3 and 7. The pair prices the sector's ladder: the market values proven scale still losing money above early profit still proving scale, by a wide margin.
Comparison updated 2026-07-10.
| Metric | CAI | NTRA |
|---|---|---|
| Price | $18.52 | $260.64 |
| Market cap | $5.2B | $36.9B |
| Sector | Medical Diagnostics | Medical Diagnostics |
| Stage | Growth | Growth |
| P/E | 52.9 | — |
| P/B | 8.82 | 20.79 |
| P/S | 5.77 | 14.75 |
| EV/EBITDA | 37.2 | — |
| Revenue growth | +91.2% | +36.4% |
| Operating margin | 2.4% | -13.4% |
| Net margin | 3.8% | -9.1% |
| Return on equity | 5.7% | -12.8% |
| Return on assets | 2.9% | -8.7% |
| Return on invested capital | 8.8% | -13.8% |
| FCF yield | 2.4% | 0.3% |
| Debt / equity | 0.64 | 0.05 |
| Current ratio | 7.05 | 2.96 |
| Altman Z (solvency) | 4.14 | 5.81 |
| Piotroski F (quality) | 5 / 9 | 4 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.